Submit Manuscript  

Article Details


Mechanisms and Treatment Progress of Rituximab-Resistance in Diffuse Large B-cell Lymphoma

[ Vol. 19 , Issue. ]

Author(s):

Li Yang*, Linqing Zou*, Siyu Gu, Lingling Kong, Shiqi Sun, Guoqi Song and William C ChoPages 1-7 (7)

Abstract:


Diffuse large B-cell lymphoma (DLBCL) is the most common subtype B non-Hodgkin lymphoma in adults. After rituximab being introduced to treatment DLBCL, the current first-line treatment used is R-CHOP regimen. This regimen greatly improves the patient's prognosis, however, relapsed or refractory cases are commonly seen, mainly due to resistance to rituximab. Although a large number of experiments have been conducted to investigate rituximab resistance, the exact mechanisms and solutions are still unclear. This review mainly describes the possible mechanisms of rituximab resistance and current new effective treatments for Rituximab-resistance in DLBCL.

Keywords:

DLBCL; Rituximab resistance; Promising treatments

Affiliation:

Department of Hematology, Affiliated Hospital of Nantong University, Nantong, Department of Human Anatomy, Nantong University, Nantong, Department of Hematology, Affiliated Hospital of Nantong University, Nantong, Department of Hematology, Affiliated Hospital of Nantong University, Nantong, Department of Hematology, Affiliated Hospital of Nantong University, Nantong, Department of Hematology, Affiliated Hospital of Nantong University, Nantong, Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon



Read Full-Text article